Licensing Agreement (Details Textual) - USD ($)		1 Months Ended
	Oct. 06, 2015	Apr. 30, 2016	Apr. 26, 2016	Feb. 29, 2016
Payments to Acquire Management Contract Rights				$ 75,000
Stock Issued During Period, Shares, New Issues				10,746
Stock Issued During Period, Value, New Issues				$ 106,385
Payments for Nonrefundable And Noncreditable License Issuance Fee		$ 300,000
Additional Licensing Agreement Fees			$ 100,000
Payments for Minimum Quarterly Nonrefundable License Issuance Fee		25,000
Minimum [Member]
Licensing Agreement, Development Milestone Fees		250,000
Maximum [Member]
Licensing Agreement, Development Milestone Fees		$ 4,000,000
RoyaltyAgreementTerms [Member]
Other Commitments, Description		the Company shall pay Aegis royalties (the Royalties) on annual net sales of (i) pharmaceutical formulations containing the Compound as an active ingredient and (ii) Aegiss proprietary chemically synthesizable excipient(s), including without limitation the Intravail excipients ((i) and (ii) together, the Products), ranging from (A) low single digits for Products with an aggregate annual Net Sales (as defined in Exhibit 1 to the Letter Agreement) during a calendar year of $50 million or less to (B) mid-single digits for Products with Net Sales of greater than $1 billion.
Aegis Therapeutics, LLC [Member]
Payments to Acquire Management Contract Rights	$ 75,000
Licensing Agreement Value			$ 300,000
Percentage Of Shares Issued For Amendment Agreement			50.00%
Percentage Of Shares To Be Issued On Average Closing Price			75.00%
License Extension Payment Consideration			$ 150,000
Stock Issued During Period, Shares, Other	13,697
Stock Issued During Period, Value, Other	$ 106,152
Stock Issued During Period, Shares, New Issues			50,000